Believed to be the first FDA IND clearance of an allogeneic dual CAR-T therapy targeting CD19 and CD20 SAN DIEGO , July 5, 2023 /PRNewswire/ — Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and